HAYWARD, Calif., Aug. 7, 2012 /PRNewswire/ --Solta Medical, Inc. (NASDAQ: SLTM) today announced that it has closed its previously announced underwritten public offering of 6,555,000 shares of its common stock at a purchase price of $2.65 per share, which includes 855,000 shares of common stock issued upon full exercise of the underwriters' over-allotment option. Net proceeds, after underwriting discounts and commissions and estimated expenses, will be approximately $16.1 million. Canaccord Genuity acted as sole book-runner for the offering and Roth Capital Partners acted as co-manager.
Solta Medical currently intends to use the net proceeds from the offering for general corporate purposes.
The offering was made to purchasers pursuant to an effective shelf registration statement (File No. 333-181074), and a prospectus supplement and accompanying prospectus describing the terms of the offering, all of which were filed with the Securities and Exchange Commission, or SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained by contacting Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at (617) 371-3900. Electronic copies of the prospectus supplement and accompanying prospectus are also available free of charge on the website of the SEC at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Solta Medical
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The Company offers products to address a range of skin issues under the industry's six premier brands: Thermage®, Fraxel®, Liposonix®, Isolaz®, CLARO® and Clear + Brilliant®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. The Liposonix system uses advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat just beneath the skin in the treatment areas of the abdomen and flanks as a noninvasive, nonsurgical approach to aesthetic waist circumference reduction. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Clear + Brilliant is a unique, cost-effective treatment that utilizes safe, fractional laser technology to correct and prevent early signs of aging and is FDA cleared and CE marked. Since 2002, over one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of the net proceeds from the offering described above. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, general economic and/or market conditions and the factors set forth in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and the prospectus supplement related to this public offering. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
SOURCE Solta Medical, Inc.
